AegirBio AB (AegirBio AB) ROCE % : -29.74% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is AegirBio AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AegirBio AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -29.74%.

AegirBio AB ROCE % Historical Data

The historical data trend for AegirBio AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AegirBio AB ROCE % Chart

AegirBio AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-51.25

-41.25

-148.60

AegirBio AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
ROCE %	Get a 7-Day Free Trial												-628.63	-70.58	-56.45	-66.39	-29.74

AegirBio AB ROCE % Calculation

AegirBio AB's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-35.083	/	( ( (44.487 - 2.047)	+	(6.443 - 1.665) )	/ 2 )
	=	-35.083	/	( (42.44	+	4.778)	/ 2 )
	=	-35.083	/	23.609
	=	-148.60 %

AegirBio AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	-1.24	/	( ( (5.84 - 0.999)	+	(4.797 - 1.298) )	/ 2 )
	=	-1.24	/	( ( 4.841	+	3.499 )	/ 2 )
	=	-1.24	/	4.17
	=	-29.74 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

AegirBio AB (GREY:AEGBF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AegirBio AB ROCE % Related Terms

Thank you for viewing the detailed overview of AegirBio AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AegirBio AB (AegirBio AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AegirBio AB (GREY:AEGBF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AEGIR:Sweden 52Q:Germany

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.aegirbio.com

AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.

AegirBio AB (AegirBio AB) Headlines

No Headlines